Dr. Adam Scioli

The behavioral health field is witnessing a wave of promising newer interventions – from psychedelic-assisted therapy and transcranial magnetic stimulation (TMS) to GLP-1 medications showing unexpected benefits for addiction and mental health – but proving their clinical and financial value remains a critical challenge. With a focus on interventional psychiatry, this panel brings together key behavioral health stakeholders to explore how to build compelling value propositions when long-term outcome data is still emerging, upfront costs are high and reimbursement pathways remain uncertain.